<DOC>
	<DOCNO>NCT00162006</DOCNO>
	<brief_summary>The purpose study evaluate whether Immune Globulin Intravenous ( Human ) , 10 % TVR ( Triple Virally Reduced ) Solution effective safe treatment patient chronic idiopathic thrombocytopenic purpura .</brief_summary>
	<brief_title>Efficacy Safety Study 10 % Triple Virally Reduced Intravenous Immune Globulin Solution Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Age &gt; = 18 &lt; = 65 year ITP diagnose least 6 month prior study entry history , physical exam , blood count blood smear Baseline platelet count &lt; = 20 x 10 9th/L determine prior administration study drug day first infusion No IVIG treatment ITP two week prior first infusion study drug For female child bear potential , use adequate birth control measure study participation Written inform consent Serum value ALT , AST , alkaline phosphatase , total bilirubin exceed 2.5 time upper limit normal screen Renal dysfunction define serum creatinine great equal 2 mg/dL screen Underlying autoimmune lymphoproliferative disorder Uncontrolled hypertension Cardiac insufficiency NYHA III IV , coronary heart disease ( CHD ) NYHA III IV Malignancy history malignancy Documented selective IgA deficiency ( &lt; = 10 mg/dL ) Treatment another investigational drug four week prior study entry current treatment another investigational product History severe adverse reaction blood and/or blood product Pregnancy lactation Positivity HIV , HCV antibody , HBsAg History unresponsiveness IVIG define peak increment platelet count &lt; = 20,000/ÂµL coincident last IVIG treatment course prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Chronic idiopathic thrombocytopenic purpura</keyword>
</DOC>